...
首页> 外文期刊>Health policy and technology. >Rare Disease Research Roadmap: Navigating the bioinformatics and translational challenges for improved patient health outcomes
【24h】

Rare Disease Research Roadmap: Navigating the bioinformatics and translational challenges for improved patient health outcomes

机译:罕见病研究路线图:应对生物信息学和转化挑战以改善患者健康状况

获取原文
获取原文并翻译 | 示例
           

摘要

Rare disease registries have now been recognized as a global priority for progress both in monitoring and documenting the natural course, and preventing and treating rare diseases. However, a disease registry is only one element of rare disease translational research. Here, we outline what we believe are ten key components in comprehensive rare disease translational research and describe critical relationships between them. These components are: (i) client-practitioner partnerships; (ii) disease registries; (iii) biobanks; (iv) genomics and other -. omics platforms; (v) community-based and population-wide studies; (vi) bioinformatics and high performance computing; (vii) interactions with pharma to facilitate drug discovery; (viii) personalized treatments based on genotype-phenotype correlations; (ix) eHealth and a whole of life record; and (x) regulatory frameworks, particularly with regard to specimen and data sharing, and the return of results. Each component has its own inherent complexity, but if effectively integrated they will provide a comprehensive approach to the future management of rare diseases, and aid health care providers in delivering services to individuals affected with rare diseases. We demonstrate that navigation through the roadmap can provide relevant health stakeholders with a blueprint to understand the challenges and barriers which need to be overcome within and across the constituent components. The rare disease roadmap will assist decision-making at all health stakeholder levels and enable the seamless integration of new knowledge, standard operating procedures and the implementation of best practice.
机译:如今,稀有疾病登记处已被认为是监测和记录自然病程以及预防和治疗罕见病方面取得进展的全球优先事项。但是,疾病登记只是罕见疾病转化研究的一个内容。在这里,我们概述了我们认为是全面的罕见病转化研究的十个关键组成部分,并描述了它们之间的关键关系。这些组成部分是:(i)客户-从业者伙伴关系; (ii)疾病登记册; (iii)生物库; (iv)基因组学及其他-。组学平台; (v)以社区为基础的研究和全民研究; (vi)生物信息学和高性能计算; (vii)与药物相互作用以促进药物发现; (viii)基于基因型-表型相关性的个性化治疗; (ix)电子卫生保健和整个生命记录; (x)监管框架,特别是在样本和数据共享以及结果返回方面。每个组成部分都有其固有的内在复杂性,但是如果有效集成,它们将为将来的罕见病管理提供全面的方法,并帮助医疗保健提供者为受罕见病影响的个人提供服务。我们证明,通过路线图导航可以为相关的卫生利益相关者提供一个蓝图,以了解构成要素之内和之间需要克服的挑战和障碍。这种罕见的疾病路线图将有助于所有卫生利益相关方的决策,并使新知识,标准操作程序和最佳实践的实现无缝整合。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号